NCT06401395
Clinical Evaluation of A neW Management Strategy for Patients With pArKinson's disEase usiNg an Innovative telemonitorING (AWAKENING)
Not Yet Recruiting · Not Applicable · DIAMPARK · registry updated 2024-05-09
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
Parkinson's disease (PD) ranks second among neurodegenerative diseases and is a major cause of neurological motor disability. The number of PD cases doubled between 1990 and 2016. The consequences of PD, including an increased risk of falls, loss of autonomy and reduced quality of life, contribute to increased morbidity and mortality. The costs associated with falls in the elderly (a fortiori those with PD) and their consequences represent between 0.85% and 1.5% of total healthcare expenditure. There is currently no cure for PD. Treatment is symptomatic and depends on the degree of functional impairment and the age of onset. After a period of stabilization (state phase) of varying length, the clinical situation worsens because of treatment-related motor complications (motor fluctuations, on/off phenomena, dyskinesias, under/overdosing) and the appearance or worsening of disease-specific signs linked to the pathogenic process. Treatment of motor complications involves constantly adjusting doses and dosing schedules to suit each individual case, and to take account of variations in the patient's motor status over the months....
Inclusion
- Age ≥ 18 years ;
- Parkinson's disease according to MDS diagnostic criteria ;
- Classified as stage 1.5 to 3 according to the Hoehn and Yahr stages ;
- Followed by a neurologist since at least one month;
- Equipped with a smartphone or a computer or tablet with internet/cellular data access via the latter (or with the caregiver) ;
- Resident on French territory affiliated to a social security scheme.
Exclusion
- Person under guardianship, curatorship or safeguard of justice or any other administrative or judicial measure of deprivation of rights and freedom;
- Patient suffering from dementia, mental disorders, cognitive disorders, or psychiatric pathology that could compromise the patient's informed consent and/or compliance with the study protocol;
- Patient deemed non-autonomous by the investigator and without a caregiver;
- Patient already included in another interventional research study, with the exception of NS-PARK's "PRECISE-PD" cohort.